Advertisement

Allograft Transplant cancer Registry

  • Israel Penn

Abstract

Advances in our understanding of cancer derive from the recent discovery that immune deficiency is associated with an increased frequency of malignancies, particularly lymphomas. This increase has been observed both in naturally occurring diseases (23,47) and in conditions produced by iatrogenic depression of immunity (76–86). A prime example is the immunosuppressed state induced in organ transplant recipients. In 1968, we first drew attention to an increased incidence of neoplasms in this group of patients (76). Since then, we have maintained an informal allograft transplant cancer registry. Physicians from many countries have generously contributed their data. The cases reported up to September 1982 are summarized here.

Keywords

Transplant Recipient Basal Cell Carcinoma Malignant Lymphoma Renal Transplant Recipient Oncogenic Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allen, D.W. and Cole, P. Viruses and human cancer. N. Engl. J. Med., 286:70, 1972.PubMedCrossRefGoogle Scholar
  2. 2.
    Armstrong, M.Y.K., Ruddle, N.H., Lipman, M.B., and Richards, F.F. Tumor induction by immunologically activated murine leukemia virus. J. Exp. Med., 137:1163, 1973.PubMedCrossRefGoogle Scholar
  3. 3.
    Bach, F.H. Personal communication, 1981.Google Scholar
  4. 4.
    Bach, M.L., Engstrom, M.A., Bach, F.H., Etheredge, E.E., and Najarian, J.S. Specific tolerance in human kidney allograft recipients. Cell. Immunol., 3:161, 1972.PubMedCrossRefGoogle Scholar
  5. 5.
    Balls, M. and Ruben, L.N. Lymphoid tumors in amphibia: a review. Prog. Exp. Tumor Res., 10:238, 1968.Google Scholar
  6. 6.
    Bieber, C.P., Hunt, S.A., Schwinn, D.A., Jamieson, S.A., Reitz, B.A., Oyer, P.E., Shumway, N.E., and Stinson, E.B. Complications in long-term survivors of cardiac transplantation. Transplant. Proc., 13:207, 1981.PubMedGoogle Scholar
  7. 7.
    Burnet, F.M. Immunological surveillance in neoplasia. Transplant. Rev., 7:3, 1971.PubMedGoogle Scholar
  8. 8.
    Calne, R.Y., Rolles, K., White, J.G., Thiru, S., Evans, D.B., Henderson, R., Hamilton, D.L., Boone, N., McMaster, P., Gibby, O., and Williams, R. Cyclosporin-A in clinical organ grafting. Transplant. Proc, 13:349, 1981.PubMedGoogle Scholar
  9. 9.
    Caro, W.A. Tumors of the skin. In: S.L. Moschella, D.M. Pillsbury, H.J. Hurley Jr. (eds.), Dermatology. pp. 1323–1406. Philadelphia: W.B. Saunders, Co., 1975.Google Scholar
  10. 10.
    Coleman, D.V., Gardner, S.D., and Field, A.M. Human Polyomavirus infection in renal allograft recipients. Br. Med. J.3:371 1973.PubMedCrossRefGoogle Scholar
  11. 11.
    Cotton, J.R., Sarles, H.E., Remmers, A.R. Jr., Lindley, J.D., Beathard, G.A., Cottom, D.L., Fish, J.C., Townsend, C.M. Jr., and Ritzmann, S.E. The appearance of reticulum cell sarcoma at the site of antilymphocyte globulin injection. Transplantation, 16:154, 1973.PubMedCrossRefGoogle Scholar
  12. 12.
    Crawford, D.H., Thomas, J.A., Janossy, G., Sweny, P., Fernando, O.N., Moorhead, J.F., and Thompson, J.H. Epstein-Barr virus nuclear antigen positive lymphoma after Cyclosporin A treatment in patients with renal allograft. Lancet, i:355, 1980.Google Scholar
  13. 13.
    Crawford, D.H., Sweny, P., Edwards, J.M.B., Janossy, G., and Hoffbrand A.V. Long-term T-cell mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving Cyclosporin A. Lancet, i:10, 1981.CrossRefGoogle Scholar
  14. 14.
    Declerq, E. and Merigan, T.C. Current concept of interferon and interferon production. Ann. Rev. Med., 21:17, 1970.CrossRefGoogle Scholar
  15. 15.
    Dent, P.B., Fish, L.A., White, J.G., and Good, R.A. Chediak-Higashi Syndrome. Observations on the nature of the associated malignancy. Lab Invest., 15:1634, 1966.PubMedGoogle Scholar
  16. 16.
    Deodhar, S.D., Kuklinca, A.G., Vidt, D.G., Robertson, A.L., and Hazard, J.B. Development of reticulum-cell sarcoma at the site of antilymphocyte globulin injection in a patient with renal transplant. N. Engl. J. Med., 280:1104, 1969.PubMedCrossRefGoogle Scholar
  17. 17.
    Editorial: Is phenytoin carcinogenic? Lancet, ii:1071, 1971.Google Scholar
  18. 18.
    Editorial: Looking at lymphomas. Lancet, ii:306, 1979.Google Scholar
  19. 19.
    Ehrlich, P. Uber den jetzigen stand der Karzinomforschung. In: The Collected Papers of Paul Ehrlich. Vol. 2, p. 550. London: Pergamon Press, 1957.Google Scholar
  20. 20.
    Francis, D.M.A. and Shenton, B.K. Blood transfusion and tumour growth: evidence from laboratory animals. (Letter to the Editor). Lancet, ii:871, 1981.CrossRefGoogle Scholar
  21. 21.
    Freeman, C., Berg, J.W., and Cutler, S.J. Occurrence and prognosis of extranodal lymphomas. Cancer, 29:252, 1972.PubMedCrossRefGoogle Scholar
  22. 22.
    Furth, J. Conditioned and autonomous neoplasms: a review. Cancer Res., 13:477, 1953.PubMedGoogle Scholar
  23. 23.
    Gatti, R.A. and Good, R.A. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer, 28:89, 1971.PubMedCrossRefGoogle Scholar
  24. 24.
    Geis, W.P., Iwatzuki, S., Moinar, Z., Giacchino, J.L., Kerman, R.H., Ing, T.S., and Hano, J.E. Pseudolymphoma in renal allograft recipients. Arch. Surg., 113:461, 1978.PubMedCrossRefGoogle Scholar
  25. 25.
    Gershwin, M.E. and Steinberg, A.D. Loss of suppressor function as a cause of lymphoid malignancy. Lancet, ii:1174, 1973.CrossRefGoogle Scholar
  26. 26.
    Giraldo, G., Beth, E., and Hagenau, F. Herpes-type virus particles in tissue culture of Kaposi’s sarcoma from different geographical regions. J. Natl. Cancer Inst., 49:1509, 1972.PubMedGoogle Scholar
  27. 27.
    Gisser, S.D. Papovavirus and squamous cell carcinoma. Human Pathol., 12:190, 1981.CrossRefGoogle Scholar
  28. 28.
    Gleichmann, E., Gleichmann, H., Schwartz, R.S., Weinblatt, A., and Armstrong, M.Y.K. Immunologic induction of malignant lymphoma: identification of donor and host tumors in the graft-versus-host model. J. Natl. Cancer Inst., 54:l07. 1975.Google Scholar
  29. 28A.
    Giovanella, B., Nilsson, K., Zech, L., Yim, O., Klein, G., and Stehlin, J.S. Growth of diploid, Epstein-Barr virus-carrying human lymphoblastoid cell lines heterotransplanted into nude mice under immunologically privileged conditions. Int. J. Cancer, 24:103, 1979.PubMedCrossRefGoogle Scholar
  30. 29.
    Gossett, T.C., Gale, R.P., Fleischman, H., Austin, G.E., Sparkes, R.S., and Taylor, C.R. Immunoblastic sarcoma in donor cells after bone-marrow transplantation. N. Engl. J. Med., 300:904, 1979.PubMedCrossRefGoogle Scholar
  31. 30.
    Gresser, I. Antitumor effects of Interferon. In: F.F. Becker (ed.), Cancer. A Comprehensive Treatise. Vol. 5, pp. 521–571. New York: Plenum Press, 1977.Google Scholar
  32. 31.
    Grossberg, S.E. The interferons and their inducers: molecular and therapeutic considerations. N. Engl. J. Med., 287:13, 79, 122, 1972.PubMedCrossRefGoogle Scholar
  33. 32.
    Gupta, P.K., Pinn, V.M., and Taft, D.D. Cervical dysplasia associated with azathioprine (Imuran) therapy. Acta Cytol., 13:373, 1969.PubMedGoogle Scholar
  34. 33.
    Hammar, S. and Mennemeyer, R. Lymphomatoid granulomatosis in a renal transplant recipient. Hum. Pathol., 7:111, 1976.PubMedCrossRefGoogle Scholar
  35. 34.
    Hanto, D.W., Sakamoto, K., Purtilo, D.T., Simmons, R.L., and Najarian, J.S. The Epstein-Barr virus in the pathogenesis of post-transplant lymphoproliferative disorders. Surgery, 90:204, 1981.PubMedGoogle Scholar
  36. 35.
    Harris, C.C. The carcinogenicity of anticancer drugs: a hazard in man. Cancer, 37:1014, 1976.PubMedCrossRefGoogle Scholar
  37. 36.
    Hattan, D. and Cerilli, G.J. Spontaneous reticulum cell sarcomas developing in C3H/HeJ mice on prolonged immunosuppressive therapy. Transplantation, 11:580, 1971.PubMedGoogle Scholar
  38. 37.
    Herberman, R.B. and Ortaldo, J.R. Natural killer cells: their role in defenses against disease. Science, 214:24, 1981.PubMedCrossRefGoogle Scholar
  39. 38.
    Herman, T.S., Hammond, N., Jones, S.E., Butler, J.J., Byrne, G.E. Jr., and McKelvey, E.M. Involvement of the central nervous system by non-Hodgkin’s lymphoma. The Southwest Oncology Group Experience, Cancer, 43:390, 1979.PubMedCrossRefGoogle Scholar
  40. 39.
    Hirsch, M.S., Proffitt, M.R., and Black, P.H. Autoimmunity, oncornaviruses, and lymphomagenesis. Contemp. Topics Immunobiol., 6:209, 1977.CrossRefGoogle Scholar
  41. 40.
    Hoover, R. and Fraumeni, J.F. Jr. Risk of cancer in renal transplant recipients. Lancet, ii:55, 1973.CrossRefGoogle Scholar
  42. 41.
    Hoover, R. and Fraumeni, J.F. Jr. Cancer risks in renal transplant recipients. Cited by Kinlen, L. (ref. 49), in press.Google Scholar
  43. 42.
    IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Some antineoplastic and immunosuppressive agents. Vol. 26, pp. 33. Lyon. World Health Organization, International Agency for Research on Cancer, 1981.Google Scholar
  44. 43.
    Ioachira, H.L. The stromal reaction of tumors: an expression of immune surveillance. J. Natl. Cancer Inst., 57:465, 1976.Google Scholar
  45. 44.
    Jerusalem, C. Relationship between malaria infection (Plasmodium berghei) and malignant lymphoma in mice. Z. Tropenmed. Parasitol., 19:94, 1968.PubMedGoogle Scholar
  46. 45.
    Kay, S., Frable, W.J., and Hume, D.M. Cervical dysplasia and cancer development in women on immunosuppression therapy for renal homotransplantation. Cancer, 26:1048, 1970.PubMedCrossRefGoogle Scholar
  47. 46.
    Kayhoe, D.E., Jacobs, L., Beye, K.K., and McCullough, N.B. Acquired toxoplasmosis: observations on two parasitologically proved cases treated with pyrimethamine and triple sulfonamides. N. Engl. J. Med., 257:1247, 1957.PubMedCrossRefGoogle Scholar
  48. 47.
    Kersey, J.H., Spector, B.D. and Good, R.A. Primary immunodeficiency diseases and cancer: the Immunodeficiency-Cancer Registry. Int. J. Cancer, 12:333, 1973.PubMedCrossRefGoogle Scholar
  49. 48.
    Kinlen, L.J., Sheil, A.G.R., Peto, J., and Doll, R. Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs. Br. Med. J., 2:1461, 1979.PubMedCrossRefGoogle Scholar
  50. 49.
    Kinlen, L. Immunosuppressive therapy and cancer. Cancer Surveys, in press.Google Scholar
  51. 50.
    Klein, G. Herpes viruses and oncogenesis. Proc. Natl. Acad. Sci. USA, 69:1056, 1972.PubMedCrossRefGoogle Scholar
  52. 51.
    Koranda, F.C., Dehmel, E.M., Kahn, G., and Penn, I. Cutaneous complications in immunosuppressed renal horaograft recipients. J. Am. Med. Assoc., 229:419, 1974.CrossRefGoogle Scholar
  53. 52.
    Koranda, F.C., Loeffler, R.T., Koranda, D.M. and Penn, I. Accelerated induction of skin cancers by ultraviolet radiation in hairless mice treated with immunosuppressive agents. Surg. Forum, 26:l45, 1975.Google Scholar
  54. 53.
    Krikorian, J.G., Anderson, J.L., Bieber, C.P., Penn, I., and Stinson, E.B. Malignant neoplasms following cardiac transplantation. J. Am. Med. Assoc, 240:639, 1978.CrossRefGoogle Scholar
  55. 54.
    Krikorian, J.G., Portlock, C.S., Cooney, P., and Rosenberg, S.A. Spontaneous regression of non-Hodgkin’s lymphoma: a report of nine cases. Cancer, 46:2093, 1980.PubMedCrossRefGoogle Scholar
  56. 55.
    Kripke, M.L. and Borsos, T. Immune surveillance revisited. J. Natl. Cancer Inst., 51:1393, 1974.Google Scholar
  57. 56.
    Krueger, G. The significance of immunosuppression and antigenic stimulation in the development of malignant lymphomas. In: E. Grundmann and R. Gross (eds.), The Ambivalence of Cytostatic Therapy, Recent Results in Cancer Research. Vol. 52, pp. 88–95. Berlin: Springer-Verlag, 1975.CrossRefGoogle Scholar
  58. 57.
    Kvasnicka, A. Relationship between herpes simplex and lip carcinoma IV. Selected cases. Neoplasma, 12:6l, 1965.Google Scholar
  59. 58.
    Li, F.P., Willard, D.R., Goodman, R. and Vawter, G. Malignant lymphoma after diphenylhydantoin (Dilantin) therapy. Cancer, 36:1359, 1975.PubMedCrossRefGoogle Scholar
  60. 59.
    Lipinski, M., Tursz, T., Kreis, H., Finale, Y., and Amiel, J-L. Disassociation of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity in kidney allograft recipients receiving high-dose immunosuppressive therapy. Transplantation, 29:214, 1980.PubMedCrossRefGoogle Scholar
  61. 60.
    Lukes, R.J. and Collins, R.D. Immunologic characterization of human malignant lymphomas. Cancer, 34:l488, 1974.Google Scholar
  62. 61.
    Lukes, R.J. and Tindle, B.H. Immunobiastic lymphadenopathy: a hyperimmune entity resembling Hodgkin’s disease. N. Engl. J. Med., 292:1, 1975.PubMedCrossRefGoogle Scholar
  63. 62.
    Lutzner, M.A. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull. Cancer, 65:169, 1978.PubMedGoogle Scholar
  64. 63.
    Marshall, V. Premalignant and malignant skin tumors in immunosuppressed patients. Transplantation, 17:272, 1974.PubMedCrossRefGoogle Scholar
  65. 64.
    Matas, A.J., Simmons, R.L., and Najarian, J.S. Chronic antigenic stimulation, herpes virus infection, and cancer in transplant patients. Lancet, i:1277, 1975.CrossRefGoogle Scholar
  66. 65.
    McDevitt, H.O. Regulation of the immune response by the major histocompatibility system. N. Engl. J. Med., 303:1514, 1980.PubMedCrossRefGoogle Scholar
  67. 66.
    Metcalf, D. Induction of reticular tumors in mice by repeated antigenic stimulation. Acta Unio Int. Contra Cancrun, 19:657, 1963.Google Scholar
  68. 67.
    Miller, C.T. Isoniazid and cancer risks (Letter to the Editor). J. Am. Med. Assoc., 230: 1254, 1974.CrossRefGoogle Scholar
  69. 68.
    Miller, D.G. On the nature of susceptibility to cancer. Cancer, 46:1307, 1980.PubMedCrossRefGoogle Scholar
  70. 69.
    Möller, G. and Möller, E. The concept of immunological surveillance against neoplasia. Transplant. Rev., 28:3, 1976.PubMedGoogle Scholar
  71. 70.
    Munyon, W., Kraiselburd, E., Davis, D., and Mann, J. Transfer of thymidine kinase to hymidine kinaseless L cells by infection with ultraviolet-irradiated Herpes simplex virus. J. Virol., 7:813, 1971.PubMedGoogle Scholar
  72. 71.
    Najarian, J.S., Sutherland, D.E.R., Ferguson, R.M., Simmons, R.L., Kersey, J., Mauer, S.M., Slavin, S., and Kim, T.H. Total lymphoid irradiation and kidney transplantation: a clinical experience. Transplant. Proc., 13(1):417, 1981.PubMedGoogle Scholar
  73. 72.
    Nehlsen, S.L. ATS-mediated immunosuppression and tumor risk. Behring Institute Mitteilungen, Marburg, Behringwerke AG pp. 201–203, 1972.Google Scholar
  74. 73.
    O’Neill, F.J. and Miles, C.P. Chromosome changes in human cells induced by herpes simplex, Types 1 and 2. Nature, 223:851, 1969.PubMedCrossRefGoogle Scholar
  75. 74.
    Opelz, G. Transfusions and malignancy. (Letter to the Editor) Lancet, ii:1057, 1981.CrossRefGoogle Scholar
  76. 75.
    Oyer, P.E., Stinson, E.B., Jamieson, S.W., Hunt, S., Reitz, B.A., Bieber, C.P., Schroeder, J.S., Billingham, M., and Shumway, N.E. One year experience with Cyclosporin A in clinical heart transplantation. Heart Trans., in press.Google Scholar
  77. 76.
    Penn, I., Hammond, W., Brettschneider, L., and Starzl, T.E. Malignant lymphomas in transplantation patients. Tranplant. Proc, 1:106, 1969.Google Scholar
  78. 77.
    Penn, I. Malignant tumors in organ transplant recipients. New York: Springer-Verlag, 1970.Google Scholar
  79. 78.
    Penn, I. Tumors arising in organ transplant recipients. In: G. Klein and S. Weinhouse (eds.), Advances in Cancer Research. Vol. 28, pp. 31–61. New York: Academic Press, 1978.Google Scholar
  80. 79.
    Penn, I. Host origin of lymphomas in organ transplant recipients. Transplantation, 27:214, 1979.PubMedCrossRefGoogle Scholar
  81. 80.
    Penn, I. Tumors in allograft recipients (Letter to the Editor). N. Engl. J. Med., 30:385, 1979.Google Scholar
  82. 81.
    Penn, I. Kaposi’s sarcoma in organ transplant recipients: report of 20 cases. Transplantation, 27:8, 1979.PubMedCrossRefGoogle Scholar
  83. 82.
    Penn, I. Immunosuppression and skin cancer. Clin. Plastic Surg., 7:361, 1980.Google Scholar
  84. 83.
    Penn, I. Malignant lymphomas in organ transplant recipients. Transplant Proc, 13:736, 1981.PubMedGoogle Scholar
  85. 84.
    Penn, I. The price of immunotherapy. Cur. Prob. Surg., 18(11):682, 1981.Google Scholar
  86. 85.
    Penn, I. The occurrence of cancer in immune deficiencies. Cur. Prob. Cancer, 6(10):1, 1982.CrossRefGoogle Scholar
  87. 86.
    Penn, I. Malignancies following the use of Cyclosporin A in man. Cancer Surveys, in press.Google Scholar
  88. 87.
    Porreco, R., Penn, I., Droegemueller, W., Greer, B. and Makowski, E. Gynecologic malignancies in immunosuppressed organ homograft recipients. Obstet. Gynec., 45:359, 1975.PubMedGoogle Scholar
  89. 88.
    Powell, L.C. Jr. Condyloma acuminatum: recent advances in development, carcinogenesis and treatment. Clin. Obstet. Gynecol., 21:1061, 1978.PubMedCrossRefGoogle Scholar
  90. 89.
    Prehn, R.T. Do tumors grow because of the immune response of the host? Transplant. Rev., 28:34, 1976.PubMedGoogle Scholar
  91. 90.
    Rapp, F. Question: do herpes viruses cause cancer? Answer: of course they do. J. Natl. Cancer Inst. (Editorial), 50:825, 1973.Google Scholar
  92. 91.
    Reddy, S., Pellettiere, E., Saxena, V., and Hendrickson, F.R. Extranodal non-Hodgkin’s lymphoma. Cancer, 46:1925, 1980.PubMedCrossRefGoogle Scholar
  93. 92.
    Reitz, B.A., Bieber, C.P., and Pennock, J.L. Cyclosporin A and lymphoma in non-human primates. In: R.Y. Calne and D.J.G. White (eds.), Proceedings International Symposium on Cyclosporin A. Elsevier North Holland Biomedical Press, in press.Google Scholar
  94. 93.
    Roder, J. and Duwe, A. The beige mutation in the mouse selectively impairs natural killer cell function. Nature (London), 278:451, 1979.CrossRefGoogle Scholar
  95. 94.
    Roder, J.C., Haliotis, T., Klein, M., Korec, S., Jett, J.R., Ortaldo, J., Herberman, R.B., Katz, R., and Fauci, A.S. A new immunodeficiency disorder in humans involving NK cells. Nature (London), 284:553, 1980.CrossRefGoogle Scholar
  96. 95.
    Schramm, G. Development of severe cervical dysplasia under treatment with azathioprine (Imuran). Acta Cytol., 14:507, 1975.Google Scholar
  97. 96.
    Schwartz, R.S. Another look at immunologic surveillance. N. Engl. J. Med., 293:181, 1975.PubMedCrossRefGoogle Scholar
  98. 97.
    Shah, K.H., Lewis, M.G., Jenson, A.B., Kurman, R.J., and Lancaster, W.D. Papillomavirus and cervical dysplasia. Lancet, ii:1190, 1980.CrossRefGoogle Scholar
  99. 98.
    Sheil, A.G.R., Mahoney, J.F., Horvath, J.S., Johnson, J.R., Tiller, D.J., May, J., and Stewart, J.H. Cancer and survival after cadaveric donor renal transplantation. Transplant. Proc., 11:1052, 1979.PubMedGoogle Scholar
  100. 99.
    Sheil, A.G.R., Mahoney, J.F., Horvath, J.S., Johnson, J.R., Tiller, D.J., Stewart, J.H., and May, J. Cancer following successful cadaveric renal transplantation. Tranplant. Proc., 13: 1981.Google Scholar
  101. 100.
    Shulman, H.M., Sullivan, K.M., Weiden, P.L., McDonald, G.B., Striker, G.E., Sale, G.E., Hackman, R., Tsoi, M., Storb, R., and Thomas, E.D. Graft versus host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Amer. J. Med., 69:204, 1980.PubMedCrossRefGoogle Scholar
  102. 101.
    Southam, C.M., Tanaka, S., Arata, T., Simkovic, D., Miura, M., and Petropolos, S.F. Enhancement of responses to chemical carcinogens by nononcogenic viruses and antimetabolites. Prog. Exp. Tumor. Res. (Basel), 11:194, 1969.Google Scholar
  103. 102.
    Special report. Epidemiologic aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infections. N. Engl. J. Med., 306:248, 1932.Google Scholar
  104. 103.
    Spencer, E.S. and Andersen, H.K. Clinically evident, nonterminal infections with herpes viruses and the wart virus in immunosuppressed renal allograft recipients. Br. Med. J., 3:251, 1970.PubMedCrossRefGoogle Scholar
  105. 104.
    Stevens, D.A. Immunosuppression and virus infections. Transplant. Proc., 5:1259, 1973.PubMedGoogle Scholar
  106. 105.
    Stutman, O. Immunodepression and malignancy. Adv. Cancer Res., 22:261, 1975.PubMedCrossRefGoogle Scholar
  107. 106.
    Stutman, O. Immunological surveillance. In: Origins of Human Cancer. pp. 729–750. Cold Spring Harbor Laboratory, 1977.Google Scholar
  108. 107.
    Suciu-Foca, N., Dumitrescu, V., Lazar, C. and Nachtigal, M. Host and tumor modifications associated with serial heterotransplantation of tumors through immunologically tolerant animals. Cancer Res., 30:1681, 1970.PubMedGoogle Scholar
  109. 108.
    Taylor, C.R. Classification of lymphoma. New “thinking” on old thoughts. Arch. Pathol. Lab. Med., 102:549, 1978.PubMedGoogle Scholar
  110. 109.
    Templeton, A.C. Kaposi’s sarcoma. In: R. Andrade, S.L. Gumport, G.L. Popkin, and T.D. Rees (eds.), Cancer of the Skin. Biology-Diagnosis-Management. pp. 1183–1225. Philadelphia: W.B. Saunders Co., 1976.Google Scholar
  111. 110.
    Thomas, L. Discussion of Medawar, P.B. Reactions to homologous tissue antigens in relation to hypersensitivity. In: H.S. Lawrence (ed.), Cellular and Humoral Aspects of the Hypersensitive States. pp. 529–532. New York: Paul Hoeber, 1959.Google Scholar
  112. 111.
    Walford, R.L. and Hildemann, W.H. Life span and lymphomaincidence of mice injected at birth with spleen cells across a weak histocompatibility locus. Amer. J. Pathol., 47:713, 1965.Google Scholar
  113. 112.
    Warner, T.F.C.S. and O’Loughlin, S. Kaposi’s sarcoma: a byproduct of tumor rejection. Lancet, ii:687, 1975.CrossRefGoogle Scholar
  114. 113.
    Weintraub, J. and Warnke, R.A. Lymphoma in cardia allograft recipients. Clinical and histological features and immunological phenotype. Transplantation, 33:347, 1982.PubMedCrossRefGoogle Scholar
  115. 114.
    Wentz, W.B., Reagan, J.W., Heggie, A.D., Fu, Y-S., and Anthony, D.D. Induction of uterine cancer with inactivated herpes simplex virus, 1 and 2. Cancer, 48:1783, 1981.PubMedCrossRefGoogle Scholar
  116. 115.
    Wyburn-Mason, R. Malignant change arising in tissues affected by herpes. Br. Med. J., 2:106, 1955.CrossRefGoogle Scholar
  117. 116.
    Wyburn-Mason, R. Malignant change following herpes simplex. Brit. Med. J., 2:6l5, 1957.Google Scholar
  118. 117.
    Zarling, J.M., Robins, H.I., Raich, P.C., Bach, F.H., and Bach, M.L. Generation of cytotoxic T lymphocytes to autologous human leukemia cells by sensitization to pooled allogeneic normal cells. Nature, 274:269, 1978.PubMedCrossRefGoogle Scholar
  119. 118.
    Zarling, J.M. and Bach, F.H. Continuous culture of T cells cytotoxic for autologous human leukemia cells. Nature, 280:685, 1979.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • Israel Penn
    • 1
  1. 1.Department of Surgery, Veterans Administration Medical CenterUniversity of Cincinnati Medical CenterCincinnatiUSA

Personalised recommendations